TL;DR
- KRAS has evolved from “undruggable” to a major oncology platform, driven by the success of G12C inhibitors.
- G12C remains the most mature segment, with approved therapies and most Phase 3 activity.
- Industry focus is shifting toward non-G12C and pan-G12 programs, particularly in high-unmet-need cancers like pancreatic cancer.
- 2024 saw a surge in KRAS program initiations, reflecting growing confidence in KRAS as a franchise opportunity.
- The key challenge ahead is translating early momentum into late-stage success and establishing the next generation of KRAS-targeted therapies.
The strategic context: KRAS went from “undruggable” to platform-defining
For decades, KRAS was treated as a graveyard of failed approaches. Developers pursued adjacent pathways—most notably EGFR and downstream signaling nodes—because direct KRAS inhibition was widely considered chemically and structurally impractical. The commercial consequence is important: lung cancer and colorectal cancer became accustomed to “upstream” inhibition (EGFR) and combination logic long before direct KRAS drugs existed.
The breakthrough was the realization that KRAS G12C creates a targetable vulnerability: a cysteine residue that enables covalent inhibitors to trap KRAS in an inactive state. Early clinical work demonstrated feasibility and set the stage for regulatory precedent.
That precedent is now real-world and durable:
- Sotorasib (Lumakras) received FDA accelerated approval for previously treated KRAS G12C-mutated NSCLC in May 2021.
- Adagrasib (Krazati) received FDA accelerated approval for KRAS G12C-mutated NSCLC in December 2022.
- In January 2025, FDA approved sotorasib + panitumumab for KRAS G12C-mutated metastatic colorectal cancer, confirming KRAS as a multi-indication platform rather than a single market event.
The result is that KRAS is no longer a “single-drug bet.” It is a platform competition spanning mutation coverage, combinations, sequencing strategy, and confirmatory expectations.
Definitions: the three mutation strategies in this analysis
To keep the landscape interpretable, we group assets into three clinically meaningful categories:
- G12C-only: Drugs that target KRAS G12C and no other G12 mutations.
- Non-G12C: Drugs that target other G12 mutations (e.g., G12D, G12V, etc.) but not G12C.
- Pan-G12: Drugs designed to target all G12 mutations (including G12C).
This framing matters because each category implies a different commercial thesis:
- G12C-only is the validated beachhead with established regulatory precedent and clearer development pathways.
- Non-G12C is the expansion frontier, especially relevant to pancreatic cancer and other high-KRAS-burden tumors.
- Pan-G12 is the platform play—higher upside, but also a heavier burden of proof on breadth, safety, and durability.
What our analysis shows: attention is rotating away from G12C-only
Our longitudinal program initiation graph shows a clear sequencing pattern that maps closely to how the market learns:
- G12C-only assets dominate early growth through roughly 2022, consistent with the timing of first approvals and follow-on investment. Once the “undruggable” narrative broke, capital and development activity concentrated where feasibility was most proven.
- Over the last several years, the center of gravity shifts toward non-G12C programs. The market is now competing for “what comes next,” particularly mutations that are more prevalent across hard-to-treat tumors such as pancreatic cancer.
This is a coherent rotation, not a random drift. G12C success did two things at once:
- it validated KRAS as a druggable platform, and
- it exposed the competitive compression that follows once multiple agents exist and combination logic begins to converge.
Why the peak in total program initiations in 2024?
The 2024 peak in overall KRAS program initiations is best interpreted as a compound effect of maturity and expansion:
- By 2024, KRAS inhibition was no longer treated as an experimental novelty; it had become a repeatable development thesis, enabling sponsors to broaden into additional KRAS mutations with greater internal confidence.
- Competitive pressure also drives breadth: sponsors launch multiple parallel shots across mutation types and indications in order to secure future optionality and avoid being boxed into a crowded single-mutation lane.
- The industry’s “platform logic” strengthened: rather than building one asset, sponsors increasingly positioned KRAS as a franchise requiring multiple mutation-specific or broader-coverage programs.
In other words, 2024 reflects the moment when KRAS moved from a single breakthrough into a broader strategic buildout.
Phase reality: innovation has shifted, but Phase 3 remains anchored in G12C-only
The phase distribution reinforces a critical executive insight: the direction of innovation and the distribution of late-stage risk are not the same thing.
- While trial initiations increasingly favor non-G12C and pan-G12 strategies, Phase 3 density remains concentrated in G12C-only assets.
- This reflects what “maturity” looks like in drug development: G12C has established patient identification workflows, known endpoints, precedents for accelerated approval, and a clearer path to confirmatory programs.
Non-G12C and pan-G12 efforts are structurally earlier because their development obstacles are greater:
- Biology is more complex (and in some cases less tractable to the same inhibitor chemistry used for G12C).
- Patient populations can be harder to define operationally, with less established screening routines in routine practice.
- Comparator and sequencing strategies are less settled, especially in pancreatic cancer, where standard-of-care outcomes remain difficult and trial timelines can be longer.
For portfolio leaders, the interpretation is clear: the market is expanding KRAS coverage, but late-stage credibility still resides in G12C. The next wave is not yet “de-risked”—it is still a capital allocation bet.
Indications: three diseases carry most of the investable story
When we exclude general “solid tumor” basket trials—typically Phase 1 discovery vehicles used to explore signals across multiple cancers—the indication landscape concentrates into three primary arenas:
- NSCLC – operationally mature KRAS testing, scalable trial execution, and clear commercial stakes.
- Colorectal cancer (CRC) – a large market with meaningful KRAS prevalence, but historically more resistant and often requiring combination strategies (notably EGFR co-inhibition).
- Pancreatic cancer – the highest unmet need segment and a mutation-driven priority, particularly for non-G12C KRAS variants.
A key pattern in the indication breakdown is that pancreatic cancer is significant in two categories but barely exists in the third. The most plausible explanation is a combination of biology and economic feasibility:
- Pancreatic KRAS biology is dominated by non-G12C mutations, particularly G12D, which naturally concentrates activity in the non-G12C and, to some extent, pan-G12 lanes.
- G12C-only programs have less incentive to prioritize pancreas because the addressable mutation prevalence is smaller, and the development and commercial bar is high; sponsors often concentrate first where probability of success and return on investment are clearer (NSCLC and CRC).
- This also reflects clinical practice: screening and molecular stratification have long been routine in NSCLC; in pancreatic cancer, broad molecular testing is growing but has historically been less uniformly embedded.
In short, mutation prevalence plus execution economics likely explains why pancreatic investment concentrates away from G12C-only.
Competitive and regulatory friction: a category under scrutiny
As KRAS matured into a marquee class, it began to attract more scrutiny—not only in clinical performance, but also in claims discipline. In 2024, FDA publicly criticized Bristol Myers Squibb for misleading efficacy claims related to Krazati marketing materials—an example of how high-profile oncology categories can face compliance pressure alongside clinical pressure.
This matters for strategy teams because it signals the next phase of competition: it won’t just be molecule-versus-molecule. It will be evidence quality, endpoint framing, and careful alignment between data and claims, particularly in crowded segments where differentiation depends on nuance.
What this means: KRAS is becoming a two-speed market
Our analysis supports a clear executive interpretation:
- G12C-only is the “mature speed”: late-stage, competitive, and increasingly defined by combination strategy, sequencing, and differentiation under crowded conditions.
- Non-G12C and pan-G12 are the “optionality speed”: high attention and accelerating trial starts, but still disproportionately pre-pivotal and therefore driven by early signal quality and platform conviction.
The defining question for the next 24 months is whether non-G12C and pan-G12 programs translate today’s momentum into Phase 3 credibility—or whether the field consolidates around a smaller number of mechanistically defensible winners.
How we support decision-makers in KRAS strategy
Our benchmarking and analytics work helps teams navigate KRAS as a platform category—not a single-asset bet.
- Clinical development leaders use our data to benchmark phase progression, indication selection, and trial design patterns across mutation strategies—so programs are built for the realities of NSCLC vs CRC vs pancreatic development.
- Portfolio strategists rely on our landscape analytics to quantify where competition is concentrated (Phase 3 density in G12C) versus where the “next wave” remains speculative (non-G12C/pan-G12), supporting better capital allocation and sequencing decisions.
- BD and licensing teams use our comparative context to assess whether an asset’s mutation strategy is a credible differentiation lever—or simply a crowded positioning move—and to pressure-test timelines against precedent.
Bottom line: KRAS is no longer a proof-of-concept story. It is a platform race—where winners will be defined by mutation coverage, execution in the three core indications, and the ability to convert early enthusiasm into late-stage credibility.
For more tailored, data-rich insights, let’s talk.
